## NOTICE

## **ALTERNATIVE MEDICATION AUTHORIZATION**

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

| Ι.       | 99113995 | Octreotide |   | 50 mcg/mL | 4 | Inj. Sol. |  |  |
|----------|----------|------------|---|-----------|---|-----------|--|--|
| 99113993 | acetate  | 50 mcg/mc  | ' | Inj. Sol. |   |           |  |  |

until the following medication, appearing on the List of Medications attached to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan, is no longer out of stock:

| ( | 00839191 | Sandostatin | Novartis | 50 mcg/mL | 1 ml | Inj. Sol. | 5.05 |  | ı |
|---|----------|-------------|----------|-----------|------|-----------|------|--|---|
|---|----------|-------------|----------|-----------|------|-----------|------|--|---|

This notice has effect retroactively from 4 May 2022.

Québec, 5 July 2022

[original signed by]

MARCO THIBAULT President and Chief Executive Officer Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.